Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

severe hypertriglyceridemia

- PMLiVE

Pfizer’s meningitis vaccine ‘a breakthrough’

FDA to speed up review process for bivalent rLP2086

- PMLiVE

Celgene gets FDA OK for first oral psoriatic arthritis drug

Otezla wins US approval to treat the auto-immune disease

AstraZeneca to develop mHealth cardiovascular services

Willwork with Vodafone in a new global partnership

- PMLiVE

MedImmune appoints Dr Anand Subramony

He joins from Novartis to take up drug delivery and device development role

- PMLiVE

Alderley Park ‘will remain flagship bioscience location’

Manchester Science Parks takes over former AstraZeneca site

- PMLiVE

FDA approves migraine headband

STX-Med’s electronic Cefaly device offers drug-free treatment option

- PMLiVE

AZ launches combination diabetes drug in UK

Xigduo combines Forxiga and metformin

- PMLiVE

FDA scrutiny of alirocumab hits Regeneron and Sanofi

Regulator to assess neurocognitive effects of cholesterol drug

- PMLiVE

Lilly/Boehringer’s empagliflozin faces US approval delay

FDA cites manufacturing issues with the new diabetes drug

- PMLiVE

Translational pharmacology: the key to ensuring safe and effective dosing

Designing pharmacokinetic and toxicokinetic studies during preclinical and early phase 1 trials will maximise a candidate’s chance of safety and efficacy success

- PMLiVE

AstraZeneca loses comms head

Neil McCrae to join UK’s Royal Mail

Interview: Christopher Boulton, AstraZeneca

AstraZeneca’s director of UK marketing and medicines access on the company's increased focused on diabetes

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links